Contact Us

    • 1-631-466-5530
      44-207-097-1828
    • 1-631-207-8356
    • 45-1 Ramsey Road, Shirley, NY 11967, USA
    • Global Locations

Oncolytic Viruses in Head and Neck Squamous Cell Carcinoma Treatment

Introduction of Head and Neck Squamous Cell Carcinoma (HNSCC)

HNSCC continues to be the sixth leading cause of cancer. Tumor recurrences affect 40%-50% of HNSCC patients owing to field cancerization. Currently available therapeutic modalities for advanced HNSCC, such as surgery with radiotherapy or chemotherapy, are of limited efficacy, and often result in severe cosmetic deformity, significant functional deficits in speech and swallowing, local radionecrosis, fibrosis, chronic pain, muscle atrophy, and xerostomia. Over the past 30 years, overall survival has not significantly improved, thus, new therapeutic approaches are needed for HNSCC. Recently, engineered and naturally oncolytic viruses have demonstrable local and systemic efficacy in many cancer types. Targeted oncolytic viruses may be a treatment that can improve morbidity and mortality of HNSCC.

Oncolytic Viruses in Head and Neck Squamous Cell Carcinoma Treatment

Oncolytic Virus for the Treatment of HNSCC

Adenoviruses, double-stranded DNA viruses, are a group of many viruses that are responsible for transient upper respiratory infection and are uniquely suited for the treatment of HNSCC. They have been engineered to become conditionally replicative adenoviruses.

Reference

  1. Malhotra, A.; et al. Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic virotherapy. 2015, 4:83.

Please feel free to contact us for a quote and further discussion with our scientists.

All services and products are for lab research only, not for any clinical use.

Online Inquiry

  • Verification code
    Click image to refresh the verification code.

Contact Us

  • 1-631-466-5530
    44-207-097-1828
  • 1-631-207-8356

Contact Us

Copyright © 2007 - 2021 Creative Biolabs. All Rights Reserved